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a B S T r a c T
Over the last decade transbronchial lung cryobiopsy (TBLc) has proven to be an “innovative application” of an “old procedure” for the histologic 
diagnosis of diffuse interstitial lung diseases (diLds). Thus, the technique of TBL cryobiopsy is now adopted for diagnostic purposes, trans-
bronchially in peripheral airways to sample lung parenchyma, whereas this same technique was traditionally employed in the past for therapeutic 
purposes, essentially for the management of malignant obstruction of central airways. When patients with interstitial lung diseases (iLds) need 
histopathological data in their diagnostic pathway, this bioptic approach could be a valid alternative to surgical lung biopsy, that is still the gold 
standard at the moment. TBL cryobiopsy has a good safety profile, its sensitivity and specificity appear good overall in idiopathic pulmonary fi-
brosis. In the last ten years, many papers have been published about this procedure defining modalities by which cryobiopsy should be performed. 
These studies have shown that TBL cryobiopsy is feasible, it allows to obtain larger lung parenchymal specimens (3 times larger than “classic” 
transbronchial biopsies), characterized by unaltered and artefact-free morphology, and it represents a safe and poorly invasive diagnostic tool 
for the histologic diagnosis of iLds. The technical aspects are really important, and they still need a complete standardization. TBL cryobiopsy 
should be part of an equipment of the modern interventional pulmonologist, who should know indications and contraindications of this methodic 
and the technical aspects of the procedure. This is a complex procedure requiring to be performed by endoscopists working in specialized centers 
with specific knowledge of DILDs, and a multidisciplinary approach, which represent pre-requisites for admission to training in this procedure.
(Cite this article as: Barisione e, Salio m, romagnoli m, Praticò a, Bargagli e, corbetta L. competence in transbronchial cryobiopsy. Panminerva 
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interstitial lung diseases (iLd) are a group of lung diseas-es that can be either of known or unknown cause; accord-
ing to the statement of the american Thoracic Society and 
the european respiratory Society,1 iLd with known cause 
include the pneumoconiosis, iLd associated with connec-
tive tissue disease (cTd-iLd), and hypersensitivity pneu-
monitis (HP); iLd with unknown cause are sarcoidosis and 
idiopathic interstitial pneumonias (iiP). iiP are another het-
erogenous entity comprising idiopathic pulmonary fibrosis 
(IPF), nonspecific interstitial pneumonia (NSIP), desqua-
mative interstitial pneumonia (diP), respiratory bronchi-
olitis with interstitial lung disease (rBiLd), acute intersti-
tial pneumonia (aiP), cryptogenic organizing pneumonia 
(cOP), and lymphoid interstitial pneumonia (LiP).
Idiopathic pulmonary fibrosis (IPF) is the most common 
of the idiopathic pulmonary fibrotic diseases and has the 
worst prognosis with a mean life expectancy of 3.8 years. 
It is defined as a chronic fibrosing interstitial pneumonia 
of unknown cause with a UiP pattern on high-resolution 
computer Tomography (HrcT) scan or on surgical lung 
biopsy.
The diagnosis of iLd relies on a combination of mul-
tiple diagnostic tools, such as imaging technics, blood test, 
lung function tests, bronchoalveolar lavage (BaL) and 
lung biopsy.
Knowledge of the diseases and indications
american Thoracic Society (aTS), european respiratory 
Society (erS), Japanese respiratory Society (JrS), and 
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ure and a new diagnosis of fibrosing ILD. Severe hypox-
ia, respiratory failure, immunocompromised status, and 
rapidly progressive disease prior to biopsy are associated 
with increased morbidity and mortality. multidisciplinary 
discussion, using the available clinical, HrcT, and SLB 
data, is useful in making a definitive diagnosis; however, 
diagnostic uncertainty may still occur in a minority of pa-
tients with iLd;4
• no recommendation was made either for or against 
transbronchial lung biopsy.
Among all TBBx, only one-third yielded a specific diag-
nosis (i.e., the diagnostic yield).2 Tommassetti et al. have 
already reported the lower predictive value of TBBx for 
UiP pattern.5 The major limitation of this evidence could 
be that the studies did not stratify patients according to 
HrcT pattern. it was argued that patients whose HrcT 
pattern is probable UiP, indeterminate, or an alternative 
diagnosis are significantly more likely to have an etiology 
detectable by TBBx (e.g., sarcoidosis) than patients with 
an HrcT pattern of UiP. Thus, if patients had been strati-
fied according to their HRCT pattern, the diagnostic yield 
and number of SLBs avoided would probably have been 
higher among those with an HrcT pattern of probable 
UiP, indeterminate, or an alternative diagnosis and lower 
among those with an HrcT pattern of UiP;
• no recommendation was made either for or against 
transbronchial cryobiopsy.
Pooling studies (unweighted) indicated that lung cryo-
biopsy obtained an adequate sample in the vast majority of 
cases. Among the adequate samples, a specific diagnosis 
was obtained in more than four- fifths of cases, with the 
remaining deemed unclassifiable. Among lung cryobiopsy 
procedures, the majority yielded an adequate specimen 
for a specific diagnosis. Additional complications includ-
ed exacerbations, mild bleeding (e.g., requiring suction 
to clear but no other endoscopic procedures), moderate 
bleeding (e.g., requiring endoscopic procedures like bron-
chial occlusion-collapse and/or instillation of ice-cold sa-
line), and severe bleeding (e.g., causing hemodynamic or 
respiratory instability, requiring tamponade or other surgi-
cal interventions, transfusions or admission to the inten-
sive care unit). although the panel was enthusiastic about 
the desirable consequences of lung cryobiopsy (adequate 
specimens in 96%, SLB avoided in 80%), this was offset 
by concern about the undesirable consequences (nondi-
agnostic in 20%, risk of procedural complications), lack 
of standardized procedure and approach (i.e. how many 
specimens should be obtained to optimize diagnostic yield 
while minimizing complications? From which portion of 
Latin american Thoracic Society (aLaT) published the 
revision of the diagnostic recommendations in 2018.2
in this document, the new principal recommendations 
regarding bronchoscopic procedures are the following:
• performing BaL cellular analysis for HrTc pattern 
of probable UiP, indeterminate and alternative diagnosis, 
but not for HrTc pattern of UiP.
There was general agreement that BaL is appropriate 
when the radiologic differential diagnosis includes eosino-
philic pneumonia, sarcoidosis, or infection.2
in 2009, Oshimo et al. investigated the role of BaL in 
the diagnosis of known causes of interstitial pneumonia, 
particularly hypersensitivity pneumonitis.3
Some BaL cell type proportions were markedly differ-
ent in patients with iPF compared with patients with other 
iLds. Patients with iPF had a slightly increased propor-
tion of eosinophils compared with healthy individuals but 
a markedly lower proportion of eosinophils than patients 
with eosinophilic pneumonia; thus, patients with a mark-
edly elevated proportion of eosinophils are more likely to 
have eosinophilic pneumonia than iPF. Patients with iPF 
had a similar to slightly higher proportion of lymphocytes 
and cd4/cd8 ratio in their BaL than healthy individu-
als but a markedly lower proportion of lymphocytes and 
cd4/cd8 ratio in their BaL than patients with sarcoid-
osis; thus, patients with a markedly elevated proportion of 
lymphocytes and cd4/cd8 ratio are more likely to have 
sarcoidosis than iPF;2
• performing surgical lung biopsy for HrTc pattern of 
probable UiP, indeterminate and alternative diagnosis, but 
not for HrTc pattern of UiP.
The surgical lung biopsy could be performed when the 
desirable consequences (adequate specimens in 100%, di-
agnosis made in 89%) were weighed against the undesir-
able consequences (surgical complications including mor-
tality, exacerbations, respiratory infection, bleeding, pro-
longed air leak). video-assisted thoracoscopic surgery is 
the preferred approach to SLB for patients who can tolerate 
single-lung ventilation, rather than open thoracotomy.2 in 
appropriately selected patients, an SLB provides valuable 
diagnostic information that cannot be obtained by any 
other means with low risk of complication. However, an 
SLB is unnecessary when a confident UIP chest imaging 
pattern is seen on HrcT scanning in the clinical context 
of an iiP, nor is it routinely regularly needed in patients 
with a well-defined CTD-ILD and those with a specific, 
clinically significant, and temporally appropriate drug, oc-
cupational, avocational, or accidental exposure. SLBs are 
generally unhelpful in patients with acute respiratory fail-
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study for the diagnosis of iLd.10 Forty-one patients with 
radiologic evidence of iLd at the chest HrcT scan un-
derwent, during a flexible bronchoscopy, transbronchial 
conventional biopsies and transbronchial cryobiopsies, 
these last ones allowing to obtain larger biopsy samples of 
lung parenchyma (mean specimen area 5.82 mm), and a 
definitive diagnosis in a substantial number of cases.11 af-
ter this innovative study, this technique has been applied 
worldwide for the diagnosis of iLds, showing a reported 
diagnostic yield of 70% to 80%, with a much better safety 
profile than surgical lung biopsy (SLB), although several 
systematic reviews and meta-analyses have shown that 
the conclusions reached by most of the publications have 
been limited by a not negligible heterogeneity between 
studies.12
The cryosurgical equipment is relatively simple, con-
sisting of two elements: 1) the cooling agent — in the vast 
majority of reports being carbon dioxide — which is ap-
plied under high pressure through the central canal of 2) 
the cryoprobe (erBe elektromedizin GmbH, Tübingen, 
Germany). The cryoprobe consists of a long flexible in-
sulated catheter with blunt metal tip that can be inserted 
through the working channel of a flexible bronchoscope. 
The metal tip cools rapidly to extremely cold temperatures 
based on the Joule-Thomson effect. as compressed gas is 
released at a high flow rate into the tip of the probe, it rap-
idly expands and cools to a temperature of -79 °c (using 
carbon dioxide, -52 °c is the real temperature developed 
in the lung tissue) or -89 °c (using nitrous oxide) within 
few seconds.9-11 The gas then escapes down the catheter 
via an efferent channel and is vented to the atmosphere.
Core basic skills
The basic skills to perform transbronchial cryobiopsy pro-
cedures are:
• active participation within the multidisciplinary team, 
together with radiologists and pathologists;
• competency in flexible and rigid bronchoscopy;
• correct interpretation of chest HrcT scan and ability 
to locate the area in which there is the greatest probabil-
ity of obtaining adequate tissue to formulate a conclusive 
diagnosis;
• ability to position the blocker balloon, so that patient 
safety is in first place throughout the procedure;
• competency on the use of fluoroscopy to guide the 
procedures of transbronchial cryobiopsy;
• ability to perform the procedure, to reach the correct 
area and to achieve the sampling;
the lung should they be obtained? For how long should the 
probe be cooled?), and the heterogeneous rates of adverse 
events noted in previous studies. The panel concluded that 
it is reasonable for experienced centers and experts with 
a track record of performing the procedure safely to con-
tinue performing lung cryobiopsy in patients whose HrcT 
pattern is probable UiP, indeterminate, or an alternative 
diagnosis. However, the panel believed very strongly and 
recommends that such experts work toward developing 
a standardized procedure that optimizes the balance be-
tween diagnostic yield and complications. Those who have 
not yet begun to perform cryobiopsy should wait until the 
procedure has been standardized before implementing this 
into clinical practice;2
• multidisciplinary discussion, instead, remains central 
for decision-making.2
Knowledge of instruments
The procedure of transbronchial lung cryobiopsy (TBLc) 
refers to the use of an endobronchial flexible cryoprobe 
to obtain endoscopic samples of peripheral lung tissue. 
The cryosurgical equipment operates based on the Joule-
Thomson effect, which dictates that a compressed gas re-
leased at the high flow rapidly expands and create a very 
low temperature. The cooling agent is applied under high 
pressure through the central canal of the probe (erbokryo 
ca; erBe, Tübingen, Germany). carbon dioxide (cO2) 
or nitric oxide are the cooling agents commonly used. The 
gas at the tip expands due to the sudden difference in the 
pressure relative to the atmospheric pressure, resulting in 
a drop-in temperature at the tip of the probe. The gas more 
frequently used nowadays (mainly for the presence of spe-
cific regulatory rules in the majority of country hamper-
ing the use of nitric oxide in endoscopic suites) is cO2, 
although nitric oxide may achieve lower temperatures.6 
Before 2009, cryoprobe was mostly used in the palliative 
treatment of obstructing endobronchial tumors. Thus, the 
use of a flexible cryoprobe with a flexible bronchoscope 
was first described in the USA in 1996 by Mathur et al. 
for cryotherapy purposes, reporting relief of large airways 
obstruction in 90% of the cases.7 Since then, the experi-
ence with endobronchial cryotherapy for the management 
of malignant tumors and non-malignant endobronchial ob-
struction has broadened, with several published studies re-
porting favorable safety, effectiveness and cost profile.8, 9
The utilization of a cryoprobe not for palliative airways 
disobstruction, but for lung parenchyma diagnostic aims 
was first applied in 2009 by Babiak et al., in their pilot 
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• management of specimens, both in keeping it attached 
to the probe during the retraction of the flexible broncho-
scope and during the thawing of the sample;
• prevention and management of possible complica-
tions (pneumothorax, bleeding, complications related to 
local anesthesia or sedation).
Procedural description and sedation
Technically, the basic procedure consists of the follow-
ing steps: with the patient being intubated (rigid bron-
choscope or endotracheal tube) the cryoprobe is advanced 
through the working channel of the flexible bronchoscope 
into the peripheral lung, and then gas expansion activated 
for several seconds (3 to 7 seconds, depending on the use 
of the 1.9-mm probe or of the 2.4-mm probe) causing sur-
rounding parenchyma to rapidly freeze and adhere to the 
cryoprobe tip. The bronchoscope with the inserted cryo-
probe and the attached frozen biopsy is then removed en-
bloc from the airway, since the cryobiopsy is significantly 
larger than the working channel of the bronchoscope, and 
thus cannot be extracted through this channel.10 Before 
performing the biopsies, it is recommended to prophy-
lactically insert a Fogarty balloon (4 or 5 F), placed in 
the lobar bronchus near the biopsy segment, and routine-
ly inflated after sampling, to minimize the consequence 
of hemorrhage. a rigid suction tube must also be avail-
able, to be introduced inside the rigid bronchoscope, if 
needed. cryoprobe tip with frozen biopsy is then thawed 
into saline, to rapidly thaw and release the biopsy from 
the cryoprobe. Biopsy is then fixed in 4% formalin and 
embedded in paraffin, and then stained with hematoxylin-
eosin (H&e) and periodic-acid Schiff (PaS). if using a 
rigid bronchoscope without prophylactic balloon place-
ment, a long instrument (bronchoscope) should be used. 
resulting biopsies tend to be 7-10 mm in greatest dimen-
sion, significantly larger than traditional forceps biopsies 
(Figure 1, 2), and notably with lack crush artefact (Figure 
3, 4, 5).11
Beside these basic technical aspects, the procedure 
includes several further essential items, e.g. the correct 
patient selection, the operating setting and equipment, 
sedation and ventilation, the distance between activated 
cryoprobe and pleura (Figure 4, 5), optimal number of 
cryobiopsies, the management of potential correlated risks 
during and after the procedure (endobronchial hemorrhage 
and pneumothorax), the literature showing a broad range 
of procedural techniques currently in use.11 
recently, an expert Statement from the cryobiopsy 
Figure 1.—Tranbronchial cryobiopsy tights to the tip probe.
Figure 2.—Transbronchial cryobiopsy in formalin 4%.
Figure 3.—Transbronchial cryobiopsy specimen with normal lung ar-
eas alternating with dense scarring obliterating the alveolar architecture 
(patchy fibrosis).
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Working Group on Safety and Utility and a call for Stan-
dardization of the Procedure has been published, as an at-
tempt to improve the substantial procedural variability 
among centers, and the lack of a real standardization of this 
technique:13
1. Patient selection
Patients must be selected for invasive procedures, includ-
ing TBLc or SLB mainly based on mda assessment, and 
so after a multidisciplinary indication for a lung histology 
need. in general, the indications for TBLc for iLd are the 
same as for SLB. TBLc (and SLB) are not indicated in 
subjects showing HrcT images demonstrating a typical 
UiP pattern, or already having a diagnosis of connective 
tissue disease, although the expert Statement suggests 
that TBLc could sometimes be proposed in these patients, 
with the aim of obtaining more definitive data suggesting 
occult exposures or collagen vascular diseases.12 more-
over, the same statement suggests that patients with an 
acute or subacute lung disease which is not rapidly pro-
gressing, with a low probability of having acute exacer-
bation of ILD might benefit from TBLC,13 although evi-
dence is scarce, and it is difficult to predict the probability 
for acute iLd, these cases certainly need to be discussed 
and carefully evaluated case by case. in general, contrain-
dications for TBLc vary substantially across studies, but 
it can be suggested that there are no age limits, Fvc<50% 
and dLcO<35% of the predicted values are regarded as 
Figure 4.—Fluoroscopic view of the cryoprobe.
Figure 5.—The biopsies obtained in the periphery of secondary pulmo-
nary lobule are more likely to get appropriate specimens for the histolog-
ic diagnosis of UiP. The area to perform the cryobiopsy with lower risk 
of pneumothorax or bleeding is the Target area. The major risk of pneu-
mothorax is inside the Subpleural area, while the risk of severe bleeding 
increases if the biopsies are obtained in the middle third of lung.
Middle part
Medium-sized vessels, not 
complete cartilage plates 
protecting the vessels, high 
risk of severe bleeding
Central airways
Large vessels 
protected by the 
cartilage, risk of 
bleeding low and 
comparable 
to forceps 
biopsies
Subpleural area
High risk of pnemothorax
Target area
Lower risk of 
pnemothorax, 
lower bleeding 
risk due to 
small vessels
relative contraindications, and pulmonary hypertension 
may increase the bleeding risk and is therefore considered 
as a relative contraindication.13
2. Operating setting and equipment
TBLc is mainly performed with in-patient setting, but 
also out-patient setting is conducted among centers. Be-
fore starting of the procedure, the operator shall choose 
the equipment, and check that every item is properly func-
tioning and correctly prepared for the procedure, including 
all related devices, invasive and non-invasive ventilation 
support. in particular, cryoprobe must be tested within sa-
line before starting the examination, to check its correct 
functioning. Prior to the procedure, the most affected seg-
ment have been determined on the basis of imaging stud-
ies (HrcT). This is the segment to sample. ideally, two 
different lobes on the same side, with different segmental 
areas should be sampled.13
There is a substantial heterogeneity in the methodology 
used across different centers for the performance of TBLc. 
airways intubation is highly suggested and it is used by 
the majority of centers, either with rigid bronchoscope or 
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same lobe, compared to biopsies in the same segment.23 
ideally, similarly to SLB technique, TBLc should also be 
taken from 2 different lobes, but no data are available yet 
to demonstrate it.
6. The management of potential correlated risks
endobronchial hemorrhage and pneumothorax represent 
the two most frequent complications after TBLc. intuba-
tion either with the rigid bronchoscope or a flexible endo-
tracheal tube is highly recommended to maintain an access 
to the airways in case of a severe bleeding after a TBLc. 
As already mentioned, the inflation of a Fogarty balloon or 
a bronchial blocker (placed in the bronchus leading to the 
biopsied area) immediately after TBLc prevents central 
airways in case of significant bleeding.
concerning the assessment of the occurrence of pneu-
mothorax, a postprocedural chest X-ray should be per-
formed, either immediately in case of symptoms, or 2 h af-
ter the end of the procedure if the patient is asymptomatic, 
especially in case of an out-patient setting.
Other potential applications of cryoprobe
rigid cryoprobe has been used in the airways since 1968 
in the palliative treatment of obstructing endobronchial tu-
mors.8
Flexible cryoprobe can be used to perform biopsies on 
endobronchial lesions.
a prospective, randomized multicenter study24 has eval-
uated the diagnostic yield of cryobiopsies in comparison 
with forceps biopsies in 563 patients with a final diagnosis 
of cancer. A definitive diagnosis was achieved in 85.1% of 
patients randomized to conventional forceps biopsy and 
95.0% of patients who underwent cryobiopsy (P<0.001). 
There was no difference in the incidence of significant 
bleeding.
The flexible cryoprobe can also be useful for extracting 
foreign bodies from the respiratory tract.25, 26 The cryo-
probe can be used with a flexible technique or in combina-
tion with a rigid bronchoscope. The possibility of extract-
ing a foreign body depends on its composition and in par-
ticular its water content. The use of cryoprobe can reduce 
the risk of foreign-body dislocation.
Some studies evaluated the feasibility, safety and diag-
nostic value of using a flexible cryoprobe to obtain pari-
etal pleural biopsies during pleuroscopy. The efficacy of 
pleural cryobiopsy was compared only with the flexible 
forceps and not with the rigid forceps which represents the 
standard in pleuroscopy.27
with endotracheal tube,13 although some centers perform 
TBLC only with a flexible bronchoscope through laryngeal 
mask.14-16 The use of prophylactic bronchial blocker place-
ment to control bleeding is highly suggested, although 
some authors performed TBLc without the positioning of 
any bronchial blocker.17 in fact, before performing cryo-
biopsies, it is recommended to prophylactically insert a 
Fogarty balloon (4 or 5 F) or a bronchial blocker, placed in 
the lobar bronchus near the biopsy segment, and routinely 
inflated after sampling, to minimize the consequence of 
hemorrhage. a rigid suction tube should also be available, 
to introduce it inside the rigid bronchoscope, if needed.
The use of a fluoroscopic guidance during the procedure 
is mandatory, to control in real-time the right positioning 
of the cryoprobe into the lung parenchyma, and the right 
distance from the pleura at the time of the cooling.
3. Sedation and ventilation
When performing TBLc, general anesthesia or deep se-
dation and intubation are recommended.13 most of the 
centers use intubation with deep sedation.18 However, in 
some centers the procedure is conducted during conscious 
sedation, which does not seem to interfere with the final 
success of the procedure.19-21 Jet ventilation has also been 
used for TBLc in iLd, with similar incidence of pneumo-
thorax (19%), although bleeding seemed to represent an 
issue in this report which showed moderate endobronchial 
bleeding in 25% of patients, and severe bleeding in a high 
percentage (53%) of cases.22
4. Distance between cryoprobe and pleura
Once the flexible cryoprobe is introduced through the 
working channel of the bronchoscope under fluoroscopic 
guidance, it should ideally reach a sub-segmental bronchus 
that allows the probe to be perpendicular to the chest wall: 
this allows the operator to ensure that the distance from the 
wall stays at 1 cm, in order to avoid a too peripheral posi-
tioning of the cryoprobe (potentially causing pneumotho-
rax) or a too central positioning (with a risk for bleeding).
5. The optimal number and sites of cryobiopsies
The optimal number of cryobiopsies cannot be uniformly 
established, although in the majority of centers 3-5 biop-
sies are usually taken.13 The quantity of samples needed 
for diagnosis is influenced by the quality of the specimen, 
the heterogeneity and the pattern of the disease. a recent 
study suggested that there is higher diagnostic yield when 
biopsies are sampled from different segments within the 
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Theoretical and practical training
a practical training should include:28
• video and other multimedia resource;
• live session and case report;
• task trainer simulation and non-technical skill simula-
tion for training on how to manage complications within 
the multidisciplinary team, including anesthesiologist and 
nurse;
• training on animal models and cadavers;
• supervised training on patients.
Quantitative and qualitative assessment
currently, in literature, there is not a minimum of proce-
dures to be considered expert operators nor a minimum of 
one-year procedures to maintain the competence.28
Trainee should be in attendance on at least 10 procedures 
performed by expert bronchoscopists (accP). Trainee 
should perform directly, as first operator, at least 10 pro-
cedures under supervision of an expert bronchoscopist. 
Trainee should be in attendance on a session with a major 
complication of bleeding and tension pneumothorax.
The competence maintenance should be 5-10 proce-
dures/year.
For qualitative assessment, mcQ core-based question-
naires and creation of a specific STAT would be useful.
The outcome measures are the following:
• percentage (and number) of biopsies taken for every 
procedure;
• percentage of complications, in all procedures;
• outcome of complications.
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